ArticleJournal of ovarian research2025
Silencing of STX4 inhibits the proliferation, migration and invasion of ovarian cancer cells via EMT/MMP2/ CCND1 signaling pathway.
Article in Journal of ovarian research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- CPS1 promotes colorectal cancer progression by inducing EMT and activating TGF-β/Smad signaling pathway.iScience · 2026Article
- Fibronectin Is a Likely Therapeutic Target Shared by Oral and Breast Carcinomas.International journal of molecular sciences · 2026Article
- Comprehensive analysis of metabolic patterns in renal cell carcinoma: implications for prognosis and treatment.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundOvarian cancer (OC) is one of the most common malignant tumors of the female reproductive system and 55-75% of patients relapse after surgery and standard postoperative chemotherapy and radiotherapy. Syntaxin4 (STX4) is localized in the plasma membrane and plays a role in the occurrence, development, invasion and metastasis of cancer cells.
objectiveTo investigate the changes in the biological behavior and effects of STX4 gene silencing on the invasion and metastasis of OC cell lines.
methodsThe proliferation, migration and invasion abilities of two groups of OC cell lines SK-OV-3 and CAOV-3 constructed with an interfering plasmid (pLVX-shRNA1-STX4-shRNA) and a negative control plasmid (pLVX-shRNA1-nonspecific-shRNA), were examined via Cell Counting Kit-8, Transwell and scratch assays. The EMT markers vimentin and E-cadherin, MMPs (MMP1, MMP2 and MMP9) and CCND1 were used to explore the possible molecular mechanism of STX4 by which STX4 affects OC cells behavior, after which the effect of STX4 gene silencing on the proliferation of OC cells in vivo was tested.
resultsAfter STX4 silencing, the biological behaviors of ovarian cancer cells including proliferation, migration and invasion, were significantly weakened. The results revealed that the E-cadherin, MMP2 and CCND1 levels of both OC cell lines were decreased after STX4 gene silencing. Animal models of STX4 gene silencing showed the tumorigenicity of tumor cells was reduced.
conclusionWe demonstrated for the first time that STX4, an important regulator of OC progression, was associated with the growth and metastasis of OC cells through correlations with EMT, MMP2, and CCND1, suggesting its potential as a new therapeutic target for OC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.